Breast Cancer Research and Treatment, Год журнала: 2025, Номер unknown
Опубликована: Янв. 22, 2025
Язык: Английский
Discover Nano, Год журнала: 2024, Номер 19(1)
Опубликована: Март 7, 2024
Abstract Breast cancer is a complex and heterogeneous disease, encompassing various subtypes characterized by distinct molecular features, clinical behaviors, treatment responses. Categorization of based on the presence or absence estrogen receptor (ER), progesterone (PR), human epidermal growth factor 2 (HER2), leading to such as luminal A, B, HER2-positive, triple-negative breast (TNBC). TNBC, comprising around 20% all cancers, lacks expression ER, PR, HER2 receptors, rendering it unresponsive targeted therapies presenting significant challenges in treatment. TNBC associated with aggressive behavior, high rates recurrence, resistance chemotherapy. Tumor initiation, progression, are attributed stem cells (BCSCs), which possess self-renewal, differentiation, tumorigenic potential. Surface markers, self-renewal pathways (Notch, Wnt, Hedgehog signaling), apoptotic protein (Bcl-2), angiogenesis inhibition (VEGF inhibitors), immune modulation (cytokines, checkpoint inhibitors) among key targets discussed this review. However, targeting BCSC subpopulation presents challenges, including off-target effects, low solubility, bioavailability anti-BCSC agents. Nanoparticle-based offer promising approach target cellular processes implicated survival BSCS TNBC. In review, we explore nanocarrier-based approaches for BCSCs aiming overcome these improve outcomes patients. These nanoparticle-based therapeutic strategies hold promise addressing gap delivering while minimizing systemic toxicity enhancing efficacy. Graphical abstract
Язык: Английский
Процитировано
17
Biomedicines, Год журнала: 2024, Номер 12(4), С. 763 - 763
Опубликована: Март 29, 2024
Tumor-infiltrating lymphocytes (TILs) are pivotal in the immune response against breast cancer (BC), with their prognostic and predictive significance varying across BC subtypes. In triple-negative (TNBC), higher TIL levels correlate improved prognosis treatment response, guiding therapeutic strategies potentially offering avenues for de-escalation. metastatic TNBC, TILs identify patients enhanced immunotherapy response. HER2+ BC, similar to exhibits positive correlations between especially neoadjuvant settings. Luminal generally has low TILs, limited impact. Single hormone receptor-positive BCs show distinct associations, emphasizing subtype-specific considerations. ductal carcinoma situ (DCIS) display ambiguous significance, necessitating further investigation. Standardizing assessment methods is crucial unlocking full potential as biomarkers, decisions, enhancing patient care BC.
Язык: Английский
Процитировано
17
Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)
Опубликована: Фев. 18, 2025
Abstract Breast cancer, characterized by unique epidemiological patterns and significant heterogeneity, remains one of the leading causes malignancy-related deaths in women. The increasingly nuanced molecular subtypes breast cancer have enhanced comprehension precision treatment this disease. mechanisms tumorigenesis progression been central to scientific research, with investigations spanning various perspectives such as tumor stemness, intra-tumoral microbiota, circadian rhythms. Technological advancements, particularly those integrated artificial intelligence, significantly improved accuracy detection diagnosis. emergence novel therapeutic concepts drugs represents a paradigm shift towards personalized medicine. Evidence suggests that optimal diagnosis models tailored individual patient risk expected are crucial, supporting era oncology for cancer. Despite rapid advancements increasing emphasis on clinical comprehensive update summary panoramic knowledge related disease needed. In review, we provide thorough overview global status including its epidemiology, factors, pathophysiology, subtyping. Additionally, elaborate latest research into contributing progression, emerging strategies, long-term management. This review offers valuable insights Cancer Research, thereby facilitating future progress both basic application.
Язык: Английский
Процитировано
11
ESMO Open, Год журнала: 2024, Номер 9(3), С. 102903 - 102903
Опубликована: Март 1, 2024
•HER2DX assay is highly reproducible and robust intra- inter-laboratories.•HER2DX proved performance for different protocol variations including platforms.•HER2DX has proven technical reliability in predicting outcomes early-stage HER2-positive breast cancer. BackgroundHER2DX, a multianalyte genomic test, been clinically validated to predict cancer recurrence risk (relapse score), the probability of achieving pathological complete response post-neoadjuvant therapy (pCR likelihood individual ERBB2 messenger RNA (mRNA) expression levels patients with human epidermal growth factor receptor 2 (HER2)-positive This study delves into comprehensive analysis HER2DX's analytical performance.Materials methodsPrecision reproducibility HER2DX risk, pCR, mRNA scores were assessed within between laboratories using formalin-fixed paraffin-embedded (FFPE) tumor tissues purified RNA. Robustness was appraised by analyzing impact cell content instruments, reagent lots, extraction kits. Variability evaluated across intratumor biopsies platforms [RNA sequencing (RNAseq) versus nCounter], according variations.ResultsPrecision 10 FFPE samples yielded maximal standard error 0.94 (1-99 scale). High 29 tumors 20 RNAs evident (correlation coefficients >0.98). The identifying score differences >5 units ≤5.2%. No significant variability emerged based on platform kits, or TagSet thaw/freeze cycles. Moreover, displayed robustness at low (10%). Intratumor 212 (106 tumors) <4.0%. Concordance from 30 RNAseq nCounter exceeded 90.0% (Cohen's κ >0.80).ConclusionsThe quantification pCR likelihood, HER2DX, performance. Precision variations. >0.80).
Язык: Английский
Процитировано
13
The Breast, Год журнала: 2024, Номер 74, С. 103674 - 103674
Опубликована: Янв. 27, 2024
This narrative work highlights a selection of published from 2023 with potential implications for breast cancer practice. We feature publications that have provided new knowledge immediately relevant to patient care or future research. also highlight guidelines reported evidence-based consensus recommendations support practice and evaluation in diagnosis treatment. The scope selected represents various domains disciplines control, prevention treatment early advanced cancer.
Язык: Английский
Процитировано
10
British Journal of Cancer, Год журнала: 2024, Номер unknown
Опубликована: Авг. 30, 2024
Mutations in the BRCA1 and/or BRCA2 genes (BRCAm) increase risk of developing breast cancer (BC) and are found ~5% unselected patients with disease. BC resulting from a germline BRCAm (gBRCAm) has distinct clinical characteristics along increased sensitivity to DNA-damaging agents such as poly(ADP-ribose) polymerase (PARP) inhibitors platinum-based chemotherapies, potentially decreased cyclin-dependent kinase 4 6 (CDK4/6) inhibitors. Given evolving treatment landscape for gBRCAm early advanced disease settings, timely determination status is fundamental facilitate most effective strategy patients. However, many not identified due suboptimal referral rates low uptake genetic testing. We discuss current evidence differential response including outcomes PARP inhibitors, CDK4/6 well ongoing innovations potential these approaches. Current testing strategies also examined, latest guidelines on who when test gBRCAm, challenges how may be overcome.
Язык: Английский
Процитировано
10
Drugs, Год журнала: 2025, Номер unknown
Опубликована: Янв. 17, 2025
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have revolutionized the treatment of hormone-receptor positive (HR+), HER2 negative (HER2−) metastatic breast cancer, and are now also established agents in high-risk intermediate-risk HR+ early cancer. Several strategies regarding CDK4/6i combinations or continuation beyond progression been successfully evaluated setting, considered a standard care. Mechanism action resistance mechanisms against addition to endocrine represent an important research topic, for Clinically, efficient substances that usually well tolerated. However, side effects differing between reported, might lead discontinuation, including disease setting. In adjuvant palbociclib has not improved outcomes, whereas large randomized phase III trials demonstrated significant disease-free survival benefit ribociclib (NATALEE trial) abemaciclib (monarchE trial). Patient selection, duration, backbone therapy, other study details differ these pivotal trials. This review focuses on both scientific background as all available clinical data CDK4/6i, with particular emphasis their use
Язык: Английский
Процитировано
1
Cancer Letters, Год журнала: 2025, Номер 616, С. 217574 - 217574
Опубликована: Фев. 19, 2025
Язык: Английский
Процитировано
1
Journal of Clinical Oncology, Год журнала: 2024, Номер 42(30), С. 3523 - 3529
Опубликована: Июль 22, 2024
Язык: Английский
Процитировано
7
Clinical & Translational Oncology, Год журнала: 2024, Номер 26(8), С. 2060 - 2069
Опубликована: Апрель 23, 2024
This study aimed to investigate the current therapeutic management of patients with early-stage HER2-positive (HER2+) breast cancer in Spain, while also exploring perceptions surrounding HER2DX terms its credibility, clinical relevance, and impact on decision-making. Understanding these aspects is crucial for optimizing treatment strategies enhancing patient outcomes context HER2+ cancer.
Язык: Английский
Процитировано
6